Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Nadav Liam Modlin; Tammy M. Miller; James J. Rucker; Namik Kirlic; Molly Lennard-Jones; Danielle Schlosser; Scott T. Aaronson

doi:10.1016/j.jad.2023.01.077

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Nadav Liam Modlin, Tammy M. Miller, James J. Rucker, Namik Kirlic, Molly Lennard-Jones, Danielle Schlosser, Scott T. Aaronson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient's readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient's readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

Original language	English
Pages (from-to)	18-25
Number of pages	8
Journal	Journal of Affective Disorders
Volume	326
DOIs	https://doi.org/10.1016/j.jad.2023.01.077
Publication status	Published - 1 Apr 2023

Keywords

Optimizing psychedelics
Psilocybin
Psychedelic therapy
Treatment outcomes

Access to Document

10.1016/j.jad.2023.01.077

Cite this

@article{ad2fd36f4b97445b8a56bdc5e1f4210e,

title = "Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation",

abstract = "Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient's readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient's readiness for psilocybin therapy, thus increasing therapy optimization and personalization.",

keywords = "Optimizing psychedelics, Psilocybin, Psychedelic therapy, Treatment outcomes",

author = "Modlin, {Nadav Liam} and Miller, {Tammy M.} and Rucker, {James J.} and Namik Kirlic and Molly Lennard-Jones and Danielle Schlosser and Aaronson, {Scott T.}",

note = "Funding Information: NLM has received consulting fees from Compass Pathways PLC, Small Pharma Ltd. and Beckley Psytech Ltd., TMM has received research support from Compass Pathways, PLC, JRR receives grant funding from COMPASS Pathways PLC and consulting fees from Beckley PsyTech and Clerkenwell Health. NK, ML-J and DS are employees of Compass Pathways. STA has received research support from Compass Pathways and Neuronetics and consulting fees from Janssen, Compass Pathways, LivaNova, Neuronetics, Genomind and Sage Therapeutics. Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.jad.2023.01.077",

language = "English",

volume = "326",

pages = "18--25",

journal = "Journal of Affective Disorders",

issn = "0165-0327",

publisher = "Elsevier",

}

TY - JOUR

T1 - Optimizing outcomes in psilocybin therapy

T2 - Considerations in participant evaluation and preparation

AU - Modlin, Nadav Liam

AU - Miller, Tammy M.

AU - Rucker, James J.

AU - Kirlic, Namik

AU - Lennard-Jones, Molly

AU - Schlosser, Danielle

AU - Aaronson, Scott T.

N1 - Funding Information: NLM has received consulting fees from Compass Pathways PLC, Small Pharma Ltd. and Beckley Psytech Ltd., TMM has received research support from Compass Pathways, PLC, JRR receives grant funding from COMPASS Pathways PLC and consulting fees from Beckley PsyTech and Clerkenwell Health. NK, ML-J and DS are employees of Compass Pathways. STA has received research support from Compass Pathways and Neuronetics and consulting fees from Janssen, Compass Pathways, LivaNova, Neuronetics, Genomind and Sage Therapeutics. Publisher Copyright: © 2023 Elsevier B.V.

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient's readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient's readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

AB - Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient's readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient's readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

KW - Optimizing psychedelics

KW - Psilocybin

KW - Psychedelic therapy

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=85147288922&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2023.01.077

DO - 10.1016/j.jad.2023.01.077

M3 - Article

C2 - 36707036

AN - SCOPUS:85147288922

SN - 0165-0327

VL - 326

SP - 18

EP - 25

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

ER -

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this